NASDAQ, TSX: NVCN Recent Highlights Announced the 1,000th recipient of a Neovasc ReducerTM (“Reducer”) implant Company sponsored Reducer Symposium attended by over 100 attendees at the 85th Annual Conference of the German Society of Cardiology (“DGK”) Completed the conceptual work for the TF/TS TiaraTM (“Tiara”) system; planning to initiate a small clinical feasibility […]

VANCOUVER, March 21, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the fourth quarter and fiscal […]

Conference Call Scheduled for 4:30pm Eastern Time NASDAQ, TSX: NVCN VANCOUVER, March 13, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today […]

VANCOUVER, March 12, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN) announced today that it has entered into exchange agreements (“Exchange Agreements”) with the holders (“Holders”) of all of its outstanding Series A common share purchase warrants and Series E common share purchase warrants (collectively, the “Warrants”) issued pursuant […]

VANCOUVER, Feb. 26, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten public offering (the “Offering”) of 11,111,111 common shares of the Company (the “Common Shares”) at a price to the public of US$0.45 per Common Share, for aggregate gross proceeds to the […]